Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 Drugs [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
One in eight adult Americans say they've tried a GLP-1 drug, according to a recent survey. I t's not often that a class of chemical becomes a household name, but glucagon-like peptide-1, aka GLP-1, has achieved that status. A survey by KFF this week found that one in eight adults said they've taken a GLP-1 drug, which are currently targeted for patients with diabetes, obesity and heart disease, and over 80% have at least heard of them. That's in part thanks to social media, where discussion of these drugs has taken off — , for example, found that the first 100 videos shown on TikTok with #Ozempic collectively had over 70 million views. The mass interest in GLP-1 drugs has led to a business boom for the two dominant pharmaceutical players in this space, Lilly and Novo Nordisk, which sold over $7.3 billion worth of its GLP-1 drugs in the first three months of the year. And between ramped up manufacturing capacity and new drug pipelines, the pair are well positioned to continue do
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Illegal Ozempic shipments enter US through e-commerce sales [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy? [Yahoo! Finance]Yahoo! Finance
- Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan' [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan' [Yahoo! Finance]Yahoo! Finance
- Hormone Replacement Therapy Market Size to Grow USD 18280 Million by 2030 at a CAGR of 1.5% | Valuates Reports [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/10/24 - Form 6-K
- 6/3/24 - Form 6-K
- 5/28/24 - Form 6-K
- NVO's page on the SEC website